LOTTE BIOLOGICS (CEO James Park) announced on January 16 that it had presented at the "Asia-Pacific (APAC)" track of the J.P.
Radiopharmaceuticals company Telix Pharmaceuticals has provided its Q4 FY24 trading update, showing sustained revenue growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback